Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer

World Journal of Gastroenterology

Volumn 22, Issue 3, 2016, Pages 1190-1201

  Lim, Byungho ^a   Kim, Jong Hwan ^a,b   Kim, Mirang ^a,b   Kim, Seon Young ^a,b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

Author keywords

DNA methylation; Gastric cancer; Molecular subtype; Mutation; Next generation sequencing

Indexed keywords

DNA; MICRORNA; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER GENETICS; CHROMOSOMALLY UNSTABLE GASTRIC CANCER; CPG ISLAND; DNA METHYLATION; EPIGENETICS; EPSTEIN BARR VIRUS INFECTION; EPSTEIN BARR VIRUS POSITIVE GASTRIC CANCER; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOMICALLY STABLE GASTRIC CANCER; HUMAN; MICROSATELLITE INSTABILITY; MICROSATELLITE INSTABILITY HIGH GASTRIC CANCER; MUTATIONAL ANALYSIS; REVIEW; STOMACH CANCER; ANIMAL; CHROMOSOMAL INSTABILITY; CLASSIFICATION; DNA MUTATIONAL ANALYSIS; EPSTEIN BARR VIRUS; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; META ANALYSIS; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; STOMACH TUMOR; VIROLOGY;

ANIMALS; BIOMARKERS, TUMOR; CHROMOSOMAL INSTABILITY; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; EPIGENOMICS; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HERPESVIRUS 4, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICRORNAS; MICROSATELLITE INSTABILITY; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84961314185     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i3.1190     Document Type: Review

References (78)

1. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49 [PMID: 14320675]
2. Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat Rev Cancer 2003; 3: 592-600 [PMID: 12894247 DOI: 10.1038/nrc1141]
3. Chiaravalli AM, Klersy C, Vanoli A, Ferretti A, Capella C, Solcia E. Histotype-based prognostic classification of gastric cancer. World J Gastroenterol 2012; 18: 896-904 [PMID: 22408348 DOI: 10.3748/wjg.v18.i9.896]
4. Grabsch HI, Tan P. Gastric cancer pathology and underlying molecular mechanisms. Dig Surg 2013; 30: 150-158 [PMID: 23867592 DOI: 10.1159/000350876]
5. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, Cheng GH, Roberts PC, Rejto PA, Gibson NW, Pocalyko DJ, Mao M, Xu J, Leung SY. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011; 43: 1219-1223 [PMID: 22037554 DOI: 10.1038/ng.982]
6. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, Lim KH, Ong CK, Huang D, Chin SY, Tan IB, Ng CC, Yu W, Wu Y, Lee M, Wu J, Poh D, Wan WK, Rha SY, So J, Salto-Tellez M, Yeoh KG, Wong WK, Zhu YJ, Futreal PA, Pang B, Ruan Y, Hillmer AM, Bertrand D, Nagarajan N, Rozen S, Teh BT, Tan P. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012; 44: 570-574 [PMID: 22484628 DOI: 10.1038/ng.2246]
7. Lee YS, Cho YS, Lee GK, Lee S, Kim YW, Jho S, Kim HM, Hong SH, Hwang JA, Kim SY, Hong D, Choi IJ, Kim BC, Kim BC, Kim CH, Choi H, Kim Y, Kim KW, Kong G, Kim HL, Bhak J, Lee SH, Lee JS. Genomic profile analysis of diffuse-type gastric cancers. Genome Biol 2014; 15: R55 [PMID: 24690483 DOI: 10.1186/gb-2014-15-4-r55]
8. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusionnegative tumors. Cancer Discov 2014; 4: 216-231 [PMID: 24436047 DOI: 10.1158/2159-8290.CD-13-0639]
9. Sieren JC, Meyerholz DK, Wang XJ, Davis BT, Newell JD, Hammond E, Rohret JA, Rohret FA, Struzynski JT, Goeken JA, Naumann PW, Leidinger MR, Taghiyev A, Van Rheeden R, Hagen J, Darbro BW, Quelle DE, Rogers CS. Development and translational imaging of a TP53 porcine tumorigenesis model. J Clin Invest 2014; 124: 4052-4066 [PMID: 25105366 DOI: 10.1172/JCI75447]
10. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, Chan KH, Chan AS, Tsui WY, Ho SL, Chan AK, Man JL, Foglizzo V, Ng MK, Chan AS, Ching YP, Cheng GH, Xie T, Fernandez J, Li VS, Clevers H, Rejto PA, Mao M, Leung SY. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014; 46: 573-582 [PMID: 24816253 DOI: 10.1038/ng.2983]
11. Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu S, Cristescu R, Nebozhyn M, Gong L, Yue YG, Wang J, Ronghua C, Loboda A, Hardwick J, Liu X, Dai H, Jin JG, Ye XS, Kang SY, Do IG, Park JO, Sohn TS, Reinhard C, Lee J, Kim S, Aggarwal A. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat Commun 2014; 5: 5477 [PMID: 25407104 DOI: 10.1038/ncomms6477]
12. Wu RC, Wang TL, Shih IeM. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther 2014; 15: 655-664 [PMID: 24618703 DOI: 10.4161/cbt.28411]
13. Zhou J, Hayakawa Y, Wang TC, Bass AJ. RhoA mutations identified in diffuse gastric cancer. Cancer Cell 2014; 26: 9-11 [PMID: 25026207 DOI: 10.1016/j.ccr.2014.06.022]
14. Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, Yamamoto S, Tatsuno K, Katoh H, Watanabe Y, Ichimura T, Ushiku T, Funahashi S, Tateishi K, Wada I, Shimizu N, Nomura S, Koike K, Seto Y, Fukayama M, Aburatani H, Ishikawa S. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 2014; 46: 583-587 [PMID: 24816255 DOI: 10.1038/ng.2984]
15. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209 [PMID: 25079317 DOI: 10.1038/nature13480]
16. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from burkitt's lymphoma. Lancet 1964; 1: 702-703 [PMID: 14107961]
17. Burke AP, Yen TS, Shekitka KM, Sobin LH. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol 1990; 3: 377-380 [PMID: 2163534]
18. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009; 137: 824-833 [PMID: 19445939 DOI: 10.1053/j.gastro.2009.05.001]
19. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-768 [PMID: 15510157 DOI: 10.1038/ nrc1452]
20. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, Sakatani T, Takada K, Fukayama M. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 2009; 69: 2766-2774 [PMID: 19339266 DOI: 10.1158/0008-5472.CAN-08-3070]
21. Inada R, Sekine S, Taniguchi H, Tsuda H, Katai H, Fujiwara T, Kushima R. ARID1A expression in gastric adenocarcinoma: clinicopathological significance and correlation with DNA mismatch repair status. World J Gastroenterol 2015; 21: 2159-2168 [PMID: 25717252 DOI: 10.3748/wjg.v21.i7.2159]
22. Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 2012; 7: e40364 [PMID: 22808142 DOI: 10.1371/journal.pone.0040364]
23. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K, Erlich RL, Greulich H, Lawrence MS, Lennon NJ, McKenna A, Meldrim J, Ramos AH, Ross MG, Russ C, Shefler E, Sivachenko A, Sogoloff B, Stojanov P, Tamayo P, Mesirov JP, Amani V, Teider N, Sengupta S, Francois JP, Northcott PA, Taylor MD, Yu F, Crabtree GR, Kautzman AG, Gabriel SB, Getz G, Jäger N, Jones DT, Lichter P, Pfister SM, Roberts TM, Meyerson M, Pomeroy SL, Cho YJ. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488: 106-110 [PMID: 22820256 DOI: 10.1038/nature11329]
24. Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, Spanhol-Rosseto A, Klein HU, Dugas M, Schindela S, Trifonov V, Schnittger S, Haferlach C, Bassan R, Wells VA, Spinelli O, Chan J, Rossi R, Baldoni S, De Carolis L, Goetze K, Serve H, Peceny R, Kreuzer KA, Oruzio D, Specchia G, Di Raimondo F, Fabbiano F, Sborgia M, Liso A, Farinelli L, Rambaldi A, Pasqualucci L, Rabadan R, Haferlach T, Falini B. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood 2011; 118: 6153-6163 [PMID: 22012066 DOI: 10.1182/blood-2011-07-365320]
25. Puls F, Niblett A, Marland G, Gaston CL, Douis H, Mangham DC, Sumathi VP, Kindblom LG. BCOR-CCNB3 (Ewinglike) sarcoma: A clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma. Am J Surg Pathol 2014; 38: 1307-1318 [PMID: 24805859 DOI: 10.1097/ PAS.0000000000000223]
26. Ichikawa S, Ichikawa S, Ishikawa I, Takahashi T, Fujiwara T, Harigae H. Successful treatment of acute promyelocytic leukemia with a t(X; 17)(p11.4; q21) and BCOR-RARA fusion gene. Cancer Genet 2015; 208: 162-163 [PMID: 25790901 DOI: 10.1016/ j.cancergen.2015.01.008]
27. Gearhart MD, Corcoran CM, Wamstad JA, Bardwell VJ. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. Mol Cell Biol 2006; 26: 6880-6889 [PMID: 16943429 DOI: 10.1128/ MCB.00630-06]
28. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13: 2151-2157 [PMID: 17404099 DOI: 10.1158/1078-0432.CCR-06-2746]
29. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465 [PMID: 22658128 DOI: 10.1056/ NEJMoa1200694]
30. Geddert H, Zur Hausen A, Gabbert HE, Sarbia M. EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1. Anal Cell Pathol (Amst) 2010; 33: 143-149 [PMID: 20978327 DOI: 10.3233/ACP-CLO-2010-0540]
31. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res 2008; 18: 85-98 [PMID: 18157157 DOI: 10.1038/cr.2007.115]
32. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]
33. Liu J, McCleland M, Stawiski EW, Gnad F, Mayba O, Haverty PM, Durinck S, Chen YJ, Klijn C, Jhunjhunwala S, Lawrence M, Liu H, Wan Y, Chopra V, Yaylaoglu MB, Yuan W, Ha C, Gilbert HN, Reeder J, Pau G, Stinson J, Stern HM, Manning G, Wu TD, Neve RM, de Sauvage FJ, Modrusan Z, Seshagiri S, Firestein R, Zhang Z. Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer. Nat Commun 2014; 5: 3830 [PMID: 24807215 DOI: 10.1038/ncomms4830]
34. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007; 117: 60-69 [PMID: 17200707 DOI: 10.1172/ JCI30111]
35. Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, McKeown C, Sanders DS, Maher ER. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999; 8: 607-610 [PMID: 10072428]
36. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Caldas C. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001; 344: 1904-1909 [PMID: 11419427 DOI: 10.1056/NEJM200106213442504]
37. Humar B, Toro T, Graziano F, Müller H, Dobbie Z, Kwang-Yang H, Eng C, Hampel H, Gilbert D, Winship I, Parry S, Ward R, Findlay M, Christian A, Tucker M, Tucker K, Merriman T, Guilford P. Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Hum Mutat 2002; 19: 518-525 [PMID: 11968084 DOI: 10.1002/humu.10067]
38. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015; 16: e60-e70 [PMID: 25638682 DOI: 10.1016/S1470-2045(14)71016-2]
39. Dvorsky R, Blumenstein L, Vetter IR, Ahmadian MR. Structural insights into the interaction of ROCKI with the switch regions of RhoA. J Biol Chem 2004; 279: 7098-7104 [PMID: 14660612 DOI: 10.1074/jbc.M311911200]
40. Joneson T, White MA, Wigler MH, Bar-Sagi D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science 1996; 271: 810-812 [PMID: 8628998]
41. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45: 1127-1133 [PMID: 24071851 DOI: 10.1038/ng.2762]
42. Schwartz JL, Jordan R, Liber H, Murnane JP, Evans HH. TP53-dependent chromosome instability is associated with transient reductions in telomere length in immortal telomerase-positive cell lines. Genes Chromosomes Cancer 2001; 30: 236-244 [PMID: 11170280]
43. Thiel A, Ristimäki A. Targeted therapy in gastric cancer. APMIS 2015; 123: 365-372 [PMID: 25706252 DOI: 10.1111/apm.12359]
44. Janbabai G, Oladi Z, Farazmandfar T, Taghvaei T, Naghshvar F. The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR. J Cancer Res Clin Oncol 2015; 141: 1945-1952 [PMID: 25820598 DOI: 10.1007/s00432-015-1965-7]
45. Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, Shen D, Bang YJ, Im SA, Ho Kim W, Jung EJ, Grabsch HI, Kilgour E. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer 2014; 110: 967-975 [PMID: 24457912 DOI: 10.1038/bjc.2013.802]
46. de Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: A step forward. World J Gastroenterol 2013; 19: 6165-6169 [PMID: 24115812 DOI: 10.3748/wjg.v19.i37.6165]
47. Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araújo A, de Mello RA. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World J Gastroenterol 2013; 19: 6383-6397 [PMID: 24151357 DOI: 10.3748/wjg.v19. i38.6383]
48. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
49. Das K, Gunasegaran B, Tan IB, Deng N, Lim KH, Tan P. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. Cancer Lett 2014; 353: 167-175 [PMID: 25086186 DOI: 10.1016/j.canlet.2014.07.021]
50. Kim TM, Jung SH, Kim MS, Baek IP, Park SW, Lee SH, Lee HH, Kim SS, Chung YJ, Lee SH. The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers. J Pathol 2014; 234: 365-374 [PMID: 25042771 DOI: 10.1002/path.4401]
51. Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel PS, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee WK, Zhang W, Hao X. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci USA 2015; 112: 1107-1112 [PMID: 25583476 DOI: 10.1073/pnas.1422640112]
52. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; 485: 502-506 [PMID: 22622578 DOI: 10.1038/nature11071]
53. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501 [PMID: 25719666 DOI: 10.1038/nature14169]
54. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873 [PMID: 20668451 DOI: 10.1038/nature09208]
55. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012; 22: 2120-2129 [PMID: 23028188 DOI: 10.1101/gr.137596.112]
56. Ferreira AM, Tuominen I, van Dijk-Bos K, Sanjabi B, van der Sluis T, van der Zee AG, Hollema H, Zazula M, Sijmons RH, Aaltonen LA, Westers H, Hofstra RM. High frequency of RPL22 mutations in microsatellite-unstable colorectal and endometrial tumors. Hum Mutat 2014; 35: 1442-1445 [PMID: 25196364 DOI: 10.1002/humu.22686]
57. Moskalev EA, Jandaghi P, Fallah M, Manoochehri M, Botla SK, Kolychev OV, Nikitin EA, Bubnov VV, von Knebel Doeberitz M, Strobel O, Hackert T, Büchler MW, Giese N, Bauer A, Muley T, Warth A, Schirmacher P, Haller F, Hoheisel JD, Riazalhosseini Y. GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers. Oncotarget 2015; 6: 4418-4427 [PMID: 25557172]
58. Welburn JP, Cheeseman IM. The microtubule-binding protein Cep170 promotes the targeting of the kinesin-13 depolymerase Kif2b to the mitotic spindle. Mol Biol Cell 2012; 23: 4786-4795 [PMID: 23087211 DOI: 10.1091/mbc.E12-03-0214]
59. Perez-Janices N, Blanco-Luquin I, Tuñón MT, Barba-Ramos E, Ibáñez B, Zazpe-Cenoz I, Martinez-Aguillo M, Hernandez B, Martínez-Lopez E, Fernández AF, Mercado MR, Cabada T, Escors D, Megias D, Guerrero-Setas D. EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. Oncotarget 2015; 6: 368-380 [PMID: 25621889]
60. Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci 2008; 99: 1726-1733 [PMID: 18616681 DOI: 10.1111/ j.1349-7006.2008.00888.x]
61. Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res 2012; 72: 3445-3450 [PMID: 22761333 DOI: 10.1158/0008-5472. CAN-11-3919]
62. Fukayama M, Ushiku T. Epstein-Barr virus-associated gastric carcinoma. Pathol Res Pract 2011; 207: 529-537 [PMID: 21944426 DOI: 10.1016/j.prp.2011.07.004]
63. Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, Tommasi S, Pfeifer GP. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003; 18: 665-677 [PMID: 12647816]
64. Donninger H, Clark J, Rinaldo F, Nelson N, Barnoud T, Schmidt ML, Hobbing KR, Vos MD, Sils B, Clark GJ. The RASSF1A tumor suppressor regulates XPA-mediated DNA repair. Mol Cell Biol 2015; 35: 277-287 [PMID: 25368379 DOI: 10.1128/ MCB.00202-14]
65. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 2001; 61: 7034-7038 [PMID: 11585730]
66. Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, Ro JY. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 2002; 160: 787-794 [PMID: 11891177 DOI: 10.1016/ S0002-9440(10)64901-2]
67. Yamamoto H, Watanabe Y, Maehata T, Morita R, Yoshida Y, Oikawa R, Ishigooka S, Ozawa S, Matsuo Y, Hosoya K, Yamashita M, Taniguchi H, Nosho K, Suzuki H, Yasuda H, Shinomura Y, Itoh F. An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa. World J Gastroenterol 2014; 20: 3927-3937 [PMID: 24744582 DOI: 10.3748/wjg.v20.i14.3927]
68. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1 [PMID: 23550210 DOI: 10.1126/scisignal.2004088]
69. Zheng R, Blobel GA. GATA Transcription Factors and Cancer. Genes Cancer 2010; 1: 1178-1188 [PMID: 21779441 DOI: 10.117 7/1947601911404223]
70. Laverriere AC, MacNeill C, Mueller C, Poelmann RE, Burch JB, Evans T. GATA-4/5/6, a subfamily of three transcription factors transcribed in developing heart and gut. J Biol Chem 1994; 269: 23177-23184 [PMID: 8083222]
71. Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, Esteller M, Sakai H, Ren CY, Yuasa Y, Herman JG, Baylin SB. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol 2003; 23: 8429-8439 [PMID: 14612389]
72. Wen XZ, Akiyama Y, Pan KF, Liu ZJ, Lu ZM, Zhou J, Gu LK, Dong CX, Zhu BD, Ji JF, You WC, Deng DJ. Methylation of GATA-4 and GATA-5 and development of sporadic gastric carcinomas. World J Gastroenterol 2010; 16: 1201-1208 [PMID: 20222162 DOI: 10.3748/wjg.v16.i10.1201]
73. Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays 2002; 24: 811-820 [PMID: 12210517 DOI: 10.1002/bies.10136]
74. Nojima M, Suzuki H, Toyota M, Watanabe Y, Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K, Hirata K, Itoh F, Tokino T, Mori M, Imai K, Shinomura Y. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 2007; 26: 4699-4713 [PMID: 17297461 DOI: 10.1038/sj.onc.1210259]
75. Li J, Ying J, Fan Y, Wu L, Ying Y, Chan AT, Srivastava G, Tao Q. WNT5A antagonizes WNT/catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther 2010; 10: 617-624 [PMID: 20603606]
76. Hibi K, Sakata M, Yokomizi K, Kitamura YH, Sakuraba K, Shirahata R, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y. Methylation of the WNT5A gene is frequently detected in early gastric carcinoma. Hepatogastroenterology 2012; 59: 2661-2663 [PMID: 23178630 DOI: 10.5754/hge09664]
77. Chan SH, Wang LH. Regulation of cancer metastasis by microRNAs. J Biomed Sci 2015; 22: 9 [PMID: 25614041 DOI: 10.1186/s12929-015-0113-7]
78. Guo X, Xia J, Yan J. Promoter methylated microRNAs: potential therapeutic targets in gastric cancer. Mol Med Rep 2015; 11: 759-765 [PMID: 25351138 DOI: 10.3892/mmr.2014.2780]